Susquehanna International Group
ACRS icon

Susquehanna International Group’s Aclaris Therapeutics ACRS Stock Holding History

Susquehanna International Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Buy
85,600
+73,200
+590% +$247K ﹤0.01% 10727
2025
Q4 		$37.3K Buy
+12,400
New +$31.3K ﹤0.01% 11836
2025
Q2 		– Sell
-30,300
Closed -$46.4K – 12551
2025
Q1 		$46.4K Sell
30,300
-200,000
-87% -$427K ﹤0.01% 11888
2024
Q4 		$571K Buy
230,300
+203,200
+750% +$506K ﹤0.01% 8342
2024
Q3 		$31.2K Buy
27,100
+7,900
+41% +$9.69K ﹤0.01% 11527
2024
Q2 		$21.1K Buy
19,200
+5,700
+42% +$6.7K ﹤0.01% 11654
2024
Q1 		$16.7K Sell
13,500
-19,300
-59% -$23K ﹤0.01% 11852
2023
Q4 		$34.4K Sell
32,800
-384,200
-92% -$1.17M ﹤0.01% 11843
2023
Q3 		$2.86M Buy
417,000
+272,100
+188% +$2.33M ﹤0.01% 4465
2023
Q2 		$1.5M Sell
144,900
-221,600
-60% -$2.01M ﹤0.01% 5772
2023
Q1 		$2.96M Buy
366,500
+354,300
+2,904% +$4.5M ﹤0.01% 4353
2022
Q4 		$192K Buy
+12,200
New +$196K ﹤0.01% 10183
2022
Q3 		– Sell
-12,600
Closed -$176K – 13063
2022
Q2 		$176K Buy
+12,600
New +$177K ﹤0.01% 10821
2021
Q4 		– Sell
-26,000
Closed -$468K – 13021
2021
Q3 		$468K Buy
+26,000
New +$417K ﹤0.01% 9561
2021
Q2 		– Sell
-24,400
Closed -$615K – 12472
2021
Q1 		$615K Buy
+24,400
New +$477K ﹤0.01% 8992
2020
Q4 		– Sell
-11,900
Closed -$31K – 10944
2020
Q3 		$31K Buy
+11,900
New +$26.6K ﹤0.01% 10316
2019
Q2 		– Sell
-11,200
Closed -$67K – 10145
2019
Q1 		$67K Buy
+11,200
New +$74.2K ﹤0.01% 8398
2018
Q3 		– Sell
-22,900
Closed -$457K – 9095
2018
Q2 		$457K Buy
+22,900
New +$423K ﹤0.01% 6968
2017
Q4 		– Sell
-14,100
Closed -$364K – 9154
2017
Q3 		$364K Buy
+14,100
New +$378K ﹤0.01% 7066

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna International Group's ACRS Position: Q1 2026 in Review

Susquehanna International Group reduced its Aclaris Therapeutics (ACRS) stake by 59% in Q1 2026, selling an estimated $1.81M and leaving 379,930 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #7018.

Susquehanna International Group first reported a position in ACRS in Q1 2017 and has held it in 28 quarters since. The position peaked at $11.3M in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Susquehanna International Group held 379,930 shares of Aclaris Therapeutics worth $1.42M as of Q1 2026.
  • Susquehanna International Group sold 536,916 Aclaris Therapeutics shares in Q1 2026, an estimated $1.81M.
  • Aclaris Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7018 holding.
  • Susquehanna International Group first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 28 quarters since.
  • Susquehanna International Group's Aclaris Therapeutics position peaked at $11.3M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.